Los Angeles Capital Management
CORT icon

Los Angeles Capital Management’s Corcept Therapeutics CORT Stock Holding History

Los Angeles Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.7K Sell
539
-40,958
-99% -$1.53M ﹤0.01% 1719
2025
Q4 		$3M Sell
41,497
-35,583
-46% -$2.79M 0.01% 372
2025
Q3 		$6.41M Buy
77,080
+72,380
+1,540% +$5.24M 0.02% 309
2025
Q2 		$345K Sell
4,700
-44,604
-90% -$3.23M ﹤0.01% 1001
2025
Q1 		$5.63M Buy
49,304
+22,791
+86% +$1.39M 0.02% 276
2024
Q4 		$1.34M Hold
26,513
– – 0.01% 543
2024
Q3 		$1.23M Hold
26,513
– – 0.01% 581
2024
Q2 		$861K Sell
26,513
-22,306
-46% -$611K ﹤0.01% 699
2024
Q1 		$1.23M Sell
48,819
-1,400
-3% -$33.1K ﹤0.01% 630
2023
Q4 		$1.63M Sell
50,219
-9,072
-15% -$249K 0.01% 522
2023
Q3 		$1.62M Buy
59,291
+47,359
+397% +$1.37M 0.01% 503
2023
Q2 		$265K Buy
11,932
+2,037
+21% +$46.9K ﹤0.01% 1042
2023
Q1 		$214K Sell
9,895
-48,101
-83% -$1.05M ﹤0.01% 1109
2022
Q4 		$1.18M Sell
57,996
-5,000
-8% -$125K 0.01% 654
2022
Q3 		$1.61M Buy
62,996
+29,214
+86% +$782K 0.01% 556
2022
Q2 		$803K Buy
33,782
+20,360
+152% +$444K ﹤0.01% 799
2022
Q1 		$302K Buy
+13,422
New +$286K ﹤0.01% 1234
2021
Q2 		– Sell
-8,615
Closed -$205K – 1555
2021
Q1 		$205K Sell
8,615
-6,585
-43% -$176K ﹤0.01% 1535
2020
Q4 		$398K Sell
15,200
-15,620
-51% -$329K ﹤0.01% 1287
2020
Q3 		$536K Sell
30,820
-7,510
-20% -$120K ﹤0.01% 1053
2020
Q2 		$645K Buy
38,330
+20,600
+116% +$289K ﹤0.01% 1013
2020
Q1 		$211K Buy
17,730
+2,830
+19% +$35K ﹤0.01% 1158
2019
Q4 		$180K Buy
+14,900
New +$207K ﹤0.01% 1214
2019
Q1 		– Sell
-12,893
Closed -$172K – 1368
2018
Q4 		$172K Sell
12,893
-95,994
-88% -$1.27M ﹤0.01% 1215
2018
Q3 		$1.53M Buy
108,887
+49,345
+83% +$690K 0.01% 742
2018
Q2 		$936K Sell
59,542
-17,340
-23% -$302K 0.01% 924
2018
Q1 		$1.26M Sell
76,882
-72,960
-49% -$1.35M 0.01% 759
2017
Q4 		$2.71M Buy
149,842
+79,793
+114% +$1.45M 0.01% 583
2017
Q3 		$1.35M Buy
70,049
+54,460
+349% +$812K 0.01% 720
2017
Q2 		$184K Buy
+15,589
New +$169K ﹤0.01% 1158

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Los Angeles Capital Management's CORT Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Corcept Therapeutics (CORT) stake by 99% in Q1 2026, selling an estimated $1.53M and leaving 539 shares worth $21.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1719.

Los Angeles Capital Management first reported a position in CORT in Q2 2017 and has held it in 30 quarters since. The position peaked at $6.41M in Q3 2025. 351 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Los Angeles Capital Management held 539 shares of Corcept Therapeutics worth $21.7K as of Q1 2026.
  • Los Angeles Capital Management sold 40,958 Corcept Therapeutics shares in Q1 2026, an estimated $1.53M.
  • Corcept Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1719 holding.
  • Los Angeles Capital Management first reported a position in Corcept Therapeutics in Q2 2017 and has held it in 30 quarters since.
  • Los Angeles Capital Management's Corcept Therapeutics position peaked at $6.41M in Q3 2025.
  • 351 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.